Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 AM ET. CEO Randall C. Schatzman, Ph.D., will provide an overview of the company. Bolt is pioneering immuno-oncology agents, specifically Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), which aim to convert ‘cold’ tumors to ‘hot’ tumors. Their lead candidate, BDC-1001, targets HER2-expressing solid tumors and is currently in phase 1/2 clinical testing.

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will present a company overview at the 20^th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 AM ET.

A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. An archived replay will be available for 90 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists currently undergoing phase 1/2 clinical testing for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing an additional Boltbody ISAC product candidate targeting CEA (BDC-2034).

Media Contacts:
Maggie Beller or David Schull
Russo Partners, LLC
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com

Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

FAQ

What is the date and time of Bolt Biotherapeutics' presentation at the Needham Conference?

Bolt Biotherapeutics will present on April 15, 2021, at 10:15 AM ET.

Who will present at the Needham Virtual Healthcare Conference for Bolt Biotherapeutics?

CEO Randall C. Schatzman, Ph.D., will present for Bolt Biotherapeutics.

How can I access the live webcast of Bolt Biotherapeutics' presentation?

The live webcast can be accessed on Bolt's Events and Presentations page at www.boltbio.com.

What is Bolt Biotherapeutics' lead candidate for clinical testing?

Bolt's lead candidate is BDC-1001, targeting HER2-expressing solid tumors.

What is the purpose of Bolt Biotherapeutics' Boltbody ISACs?

Boltbody ISACs are designed to engage and activate myeloid cells to kill tumor cells.